Provided by Tiger Trade Technology Pte. Ltd.

Canton Strategic Holdings

1.94
-0.1200-5.83%
Post-market: 1.92-0.0182-0.94%19:34 EDT
Volume:774.94K
Turnover:1.52M
Market Cap:149.62M
PE:-0.91
High:2.09
Open:2.07
Low:1.92
Close:2.06
52wk High:9.08
52wk Low:1.08
Shares:77.12M
Float Shares:70.16M
Volume Ratio:1.08
T/O Rate:1.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1272
EPS(LYR):-9.4096
ROE:-34.42%
ROA:-11.60%
PB:0.32
PE(LYR):-0.21

Loading ...

Company Profile

Company Name:
Canton Strategic Holdings
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
12
Office Location:
34 Shrewsbury Avenue,Suite 1C,Red Bank,New Jersey,United States
Zip Code:
07701
Fax:
- -
Introduction:
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Directors

Name
Position
Mark Wendland
Director,Chairman of the Board and Chief Executive Officer
Clay Kahler
Independent Director
Jill E. Sommers
Independent Director
Pamela L. Carter
Independent Director
Rishi Nangalia
Independent Director
Sean Galvin
Independent Director
William Wiley
Independent Director

Shareholders

Name
Position
Mark Wendland
Director,Chairman of the Board and Chief Executive Officer
Angela Dominy Radkowski
Chief Operating Officer
Jacob Asbury
Chief Financial Officer
Mark Toomey
President